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Abstract
Extracellular vesicles (EVs) that are derived from stem cells are proving to be promising
therapeutic options. We herein investigate the therapeutic potential of EVs that have been
derived from different stem cell sources, bone-marrow (MSC) and human liver (HLSC), on
mesangial cells (MCs) exposed to hyperglycaemia. By expressing a dominant negative
STAT5 construct (ΔNSTAT5) in HG-cultured MCs, we have demonstrated that miR-21
expression is under the control of STAT5, which translates into Transforming Growth Factor
beta (TGFβ) expression and collagen production. A number of approaches have been used
to show that both MSC- and HLSC-derived EVs protect MCs from HG-induced damage via
the transfer of miR-222. This resulted in STAT5 down-regulation and a decrease in miR-21
content, TGFβ expression and matrix protein synthesis within MCs. Moreover, we demon-
strate that changes in the balance between miR-21 and miR-100 in the recipient cell, which
are caused by the transfer of EV cargo, further contribute to providing beneficial effects.
Interestingly, these effects were only detected in HG-cultured cells. Finally, it was found that
HG reduced the expression of the nuclear encoded mitochondrial electron transport chain
(ETC) components, CoxIV. It is worth noting that EV administration can rescue CoxIV
expression in HG-cultured MCs. These results thus demonstrate that both MSC- and
HLSC-derived EVs transfer the machinery needed to preserve MCs from HG-mediated
damage. This occurs via the horizontal transfer of functional miR-222 which directly inter-
feres with damaging cues. Moreover, our data indicate that the release of EV cargo into
recipient cells provides additional therapeutic advantages against harmful mitochondrial
signals.
PLOS ONE | DOI:10.1371/journal.pone.0162417 September 9, 2016 1 / 18
a11111
OPEN ACCESS
Citation: Gallo S, Gili M, Lombardo G, Rossetti A,
Rosso A, Dentelli P, et al. (2016) Stem Cell-Derived,
microRNA-Carrying Extracellular Vesicles: A Novel
Approach to Interfering with Mesangial Cell Collagen
Production in a Hyperglycaemic Setting. PLoS ONE
11(9): e0162417. doi:10.1371/journal.pone.0162417
Editor: Riccardo Alessandro, Universita degli Studi di
Palermo, ITALY
Received: June 28, 2016
Accepted: August 22, 2016
Published: September 9, 2016
Copyright: © 2016 Gallo et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work has been supported by grants
obtained by GC and MFB from the Associazione
Italiana per la Ricerca sul Cancro (AIRC) projects IG
12890 and IG 17630 and by grants obtained by MFB
from Ministero dell’Istruzione, Università e Ricerca
(MIUR) ex 60%.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
Diabetes is the main driver of chronic kidney disease (CKD) in the Western world and
accounts for about 50% of new cases. Almost 40% of diabetes sufferers develop diabetic
nephropathy (DN), which has thus become the leading cause of end stage renal disease (ESRD)
in urbanized countries [1]. Patients with CKD are not only at an increased risk of end-stage
renal disease, but also cardiovascular disease and death [2,3]. Novel targets for improved DN
management urgently need to be identified as ESRD can manifest despite strict glycaemic con-
trol and the application of various therapeutic approaches [4]. Key, early stage DN pathological
features include podocyte damage/loss and mesangial cell (MC) hypertrophy [5]. The subse-
quent expansion of the myofibroblast progenitor population inside kidney stroma and
increased extracellular matrix (ECM) protein synthesis lead to glomerular basement mem-
brane thickening and tubulo-interstitial fibrosis [5,6]. A number of miRs have been reported to
contribute to fibrotic processes in various pathological contexts, including DN [7]. In fact,
miR-21 has gained particular interest in the field of MC expansion [8,9]. Osipova et al. [10]
have recently reported increased concentrations of miR-21 in the urine of diabetic patients.
Various miR-21 targets have been reported to further collagen production and fibrosis [8,9,11–
13], while PTEN up-regulation, which results in the activation of the Akt-mTOR pathway,
seems to be the principle contributor to this process [9,14]. As a matter of fact, it has been
found that interfering with miR-21 reverses histological kidney abnormalities in a preclinical
model of DN [8,12]. miR genes, like other genes, can be regulated by transcription factors [15].
In this regard, miR-21 has been described as a STAT5 target gene in Jurkat cells [16], as well as
in mammary cells, in response to prolactin [17]. On the other hand, STAT5 itself can be con-
trolled by miRs, including miR-222 [18,19], and miR-223 [20], which suggests that the overall
scenario is extremely complex.
Clinical and experimental nephrologists are working in different fields to improve CKD out-
comes. In particular, essential research is underway, using in vivo and in vitromodels, which is
aimed at defining the molecular basis for the principal pathways involved in CKD progression
to ESRD and finding new therapeutic approaches to inhibiting renal fibrosis. Mesenchymal
stem cells (MSCs) of different origin are currently being extensively studied in the regenerative
medicine field [21]. Although MSCs were originally thought to home in on and engraft injured
tissues, where they would differentiate and replace damaged cells, the positive effects of MSC
transplantation have recently been proven to result from their ability to release trophic media-
tors [21]. Several studies have focused on extracellular RNA (exRNA) transporters and have
indicated that they may be present in biological fluids in the form of vesicles, including exo-
somes and microvesicles [22,23]. The inclusive term “extracellular vesicles” (EVs) has been
suggested [22,23] for these vesicles as they share overlapping features and biological activity
despite having distinct biogenesis. EVs’ role as a well-preserved evolutionary mechanism of
cell-to-cell communication has recently attracted increased attention [24]. In particular, it has
been suggested that stem cell-derived EVs may mimic the effect of their parent cells via the hor-
izontal transfer of functional RNAs, miRs, lipids and proteins in regenerative medicine [22–
26]. A comparative analysis of EV cargo and stem cell sources indicates that the specific, rather
than random, compartmentalization of different RNA species occurs [27]. The interaction
between Alix, a multifunctional protein of the endosomal sorting complex required for trans-
port, and Ago2 has recently been studied and its involvement in driving miRNAs within EVs
has been suggested [28].
Although the functions of stem cell-derived EVs have been studied in various pathological
settings, the mechanics of how EVs protect cells from damaging cues have only partially been
investigated.
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In the present study, we analyse the effects of EVs that were released from different stem cell
sources on HG-induced collagen production and mitochondria damage, while paying particu-
lar attention to their effects on STAT5A, miR-21, miR-222, miR-100 and TGFβ expression.
Materials and Methods
Reagents and antibodies are reported in S1 Table.
Cell cultures
Human mesangial cells (MCs), characterized as previously described [29], were maintained in
DMEM+10% FBS. MCs were either cultured at low (1 g/l, 5mmol/l, LG) or high D-glucose
dose (4.5 g/l, 25mmol/l, HG) for 48h for the experiments. MCs in LG or HG DMEM were also
cultured for an additional 18h without FBS, either in the presence or the absence of either
bone-marrow-derived mesenchymal stem cell (MSC) (purchased from LONZA, Euroclone)
[25,27] or human liver stem cell (HLSC)-derived EVs, isolated from adult human hepatocytes
(purchased from LONZA) as previously described [30]. The same number of EVs was used to
stimulate MCs (7000 EVs/ target cell) [31]. Endothelial cells (ECs) cultured for 48h with ox-
LDL (10 ng/ml) were used as a positive control for the senescence assay. MCs treated for 48h
with TGFβ (10 ng/ml) were used as positive control for proliferation assay and for the expres-
sion of collagen. Human fibroblasts cultured 24 hours in HG medium were used as positive
control for TGFβ production.
All experiments were performed in accordance with the European Guidelines and policies
and approved by the Ethical Committee of the University of Turin.
Isolation and quantification of MSC- and HLSC-derived EVs
MSCs and HLSCs were cultured in EndoGROMedium, without FBS, for 24 h in order to col-
lect EVs from supernatants. After being centrifuged at 3000 g for 30 min to remove debris, cell-
free supernatants were submitted to differential ultracentrifugation at 10 000 and 100 000 g
(Beckman Coulter Optima L-90K ultracentrifuge; Beckman Coulter, Fullerton, CA, USA) for
3h at 4°C. EVs were either used fresh or stored (-80°C) after re-suspension in DMEM supplied
with 1% DMSO [26]. Frozen EVs were washed and pelleted by 100k g ultracentrifugation to
remove DMSO before experiments. No difference in biological activity was observed between
fresh and stored EVs. EV protein content was quantified using the Bradford method (Bio-Rad,
Hercules, CA, USA). Possible contamination was tested for using a Limulus amebocyte assay
(concentration <0.1 ng/ml) (Charles River Laboratories, Inc., Wilmington, MA, USA). EV size
distribution analyses were performed using a NanoSight LM10 (NanoSight Ltd, Minton Park
UK). The particles in the samples were illuminated using a laser light source and the scattered
light was captured by camera and analysed using Nanoparticle Tracking Analysis (NTA). NTA
automatically tracked and sized particles according to Brownian motion and the diffusion coef-
ficient (Dt). EV characterization has been performed by Collino et al [27].
Cell proliferation
Proliferative activity in both LG and HG conditions, with or without EVs, was assayed via
direct cell count by 3 individual operators in triplicate, as previously described (number±SEM
of cells per field, 10X magnification) [32].
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Western blot analysis
MCs were lysed and protein concentrations obtained as previously described [33]. 50 μg pro-
teins were subjected to SDS-PAGE, transferred into nitrocellulose membranes and processed
as previously described [33]. Densitometric analysis was used to calculate the differences in the
fold induction of protein levels which were normalized to β-actin. Values are reported as rela-
tive amounts. To evaluate CoxIV content, MCs were lysed in RIPA buffer (Sigma-Aldrich) and
subjected to western blot. Cell supernatants from LG- or HG-cultured MCs were collected, cen-
trifuged to remove cell debris and analysed by western blot for collagen type IV content.
RNA isolation and quantitative real-time PCR (qRT-PCR)
Total RNA was isolated fromMCs using the TRIzol reagent (Invitrogen) according to manu-
facturer’s instructions. RNA was quantified spectrophotometrically (Nanodrop ND-1000, Wil-
mington, DE, USA). RNA from cells was then reverse-transcribed either using a TaqMan
microRNA RT kit, that is specific for miR-222 and miR-223, or a Syber Green microRNA RT
Kit specific for miR-21 and miR-100. Thus RNA was subjected to qRT-PCR using a TaqMan/
Syber microRNA assay kit and the ABI PRISM 7700 sequence detection system (Applied Bio-
systems, Foster City, CA, USA). miR expression was normalized to the small nuclear RNA,
RNU6B.
Gain- and loss-of-function experiments
Gain- and loss-of-function experiments were performed in MCs cultured in LG or HG that
had either been transfected with the pre-miR negative control or the pre-miR-222, pre-miR-
223 or pre-miR-100 precursor oligonucleotides (Applied Biosystem), according to manufactur-
er’s instructions. LG-cultured MCs were also transfected with either a pre-miR control or pre-
miR-21, whereas HG-cultured MCs were transfected with anti-miR negative control or anti-
miR-21 oligonucleotides. Cells were then either processed to give the cell extracts for Western
blot analyses or total RNA isolation to evaluate miR expression.
Transfer of miRs from EVs to MCs
To analyse miR-222 transfer from EVs to MCs, miR transfer experiments were conducted as
previously described by Yuan [34]. 5×105 cells/well of MCs were incubated with a transcrip-
tional inhibitor, α-amanitin [31], either in the absence or in the presence of EVs that had either
been pre-treated with RNAse or not. Total RNA fromMCs, was subjected to qRT-PCR for
miR expression. As an indirect measure of miR transfer, we determined the difference in Ct
values between α-amanitin treated cells in the absence and in the presence of EVs that had
either been pre-treated with RNAse or not; a positive value indicated transfer of miR into target
cells. If no signal was detected, a Ct value of 40 was assigned to the sample.
Transfection of dominant negative (ΔN) STAT5 construct
In selected experiments, HG-cultured MCs were either transiently transfected with an empty
vector or with the ΔNSTAT5 construct for 48h [35]. Cells were then processed for Western
blot analysis or RNA isolation.
Luciferase miRNA Target Reporter Assay
The luciferase reporter assay was performed using a construct generated by sub cloning PCR
products amplified from 3’UTR full length of STAT5A mRNA in the Sac I restriction site of
the luciferase reporter vector pGL3 (Promega, Madison, WI, USA). PCR products were
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obtained using the following primers: STAT5A: sense, 5’AAGAGCTCATGTTTGAATCCCA
CGCT3’; antisense, 5’TTGAGCTCACACAAATGTGTGGTCTT3’. The pGL3, pGL3-3’UTR
STAT5A luciferase reporter vectors were transiently co-transfected in MCs, treated as indi-
cated, at 10:1 molar ratio with the pRL vector, coding for the Renilla luciferase, used as internal
control of the luciferase assay [18]. Luciferase activities, using the pGL3 reporter vectors, above
described, were also evaluated in MCs transfected with pre-miR-222.
Senescence assay
Senescence was evaluated by measuring the acidic β-galactosidase activity of MCs that had
been differently cultured, as previously described [36].
Statistical analysis
All data are presented as mean or percentage±SEM. The D'Agostino—Pearson test was used to
test normality. Data were analysed using the Student's t-tests for two-group comparison and
using a one-way analysis of variance, followed by Tukey's multiple comparison test for 3
groups. Three experiments performed in triplicate were the minimum sample size ensuring
90% statistical power between experimental groups, with a probability level of 0.05, two-tailed
hypothesis. The cut-off for statistical significance was set at p<0.05. All statistical analyses were
carried out using GraphPad Prism version 5.04 (GraphPad Software, Inc., La Jolla, CA, USA).
Results
High glucose stimulation induces mesangial cell (MC) proliferation,
collagen type IV production and miR-21 expression
MCs were cultured in high glucose medium for 48 hours in order to mimic acute hyperglycae-
mia-mediated mesangial cell damage. Proliferation and senescence were then analysed. We
demonstrate that HG significantly increases MC proliferation (Fig 1A), as shown by cell num-
ber and cyclin D1 content (Fig 1B). No changes in the number of senescent MCs were detected
(Fig 1C). Collagen production was evaluated in MCs challenged with HG as collagen produc-
tion is a hallmark of glomerular damage [5,6]. Western blot analysis on both total cell lysates
and supernatants showed that collagen type IV production significantly increased compared to
low glucose treated cells (Fig 1D and 1E). The increase in collagen production indicates that
MCs shift to a fibrotic secretive phenotype. TGFβ already barely produced by MCs, was further
increased by HG treatment (Fig 1F). miR-21, well-known for being involved in diabetic
nephropathy, is also known to induce mesangial cell matrix expansion [8,11]. In fact, we found
that HG treatment induces miR-21 expression (Fig 1G). Its role in regulating the PTEN-
mTOR signalling pathway has been reported in numerous cell types [8,9,11,14] leading us to
investigate the involvement of this signalling pathway. As reported in Fig 1H, we found low
level of PTEN and high level of mTOR even in HG treated MCs.
EVs released from MSCs and HLSCs inhibit collagen production and
miR-21 expression in MCs
The effect of EVs recovered fromMSCs and HLSCs on MC proliferation and collagen produc-
tion in LG- and HG-cultured MCs was evaluated. EVs did not interfere with MC proliferation
as shown in Fig 2A. However, EVs recovered fromMSCs and HLSCs significantly reduced col-
lagen production in MCs (Fig 2B). Furthermore, down-regulated miR-21 (Fig 2C), mTOR (Fig
2D) and TGFβ expression were detected in MCs (Fig 2E). Consistently, up-regulation of PTEN
was detected (Fig 2D).
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Fig 1. Mesangial cell (MC) proliferation and collagen type IV production upon short term high glucose (HG) treatment. (A) A cell
proliferation assay was performed in MCs treated for 48h as indicated and reported as number of cells per field (20Xmagnification). Data
are expressed as mean±SEM (n = 6) (p = 0.006, HG-treated MCs vs LG-treated MCs; p = 0.004, TGFβ-treated MCs (+; 10 ng/ml) vs LG-
treated MCs). (B) Cell extracts fromMCs treated with either LG, HG or TGFβ (+) were analysed for cyclin D1 content, normalized to β-
actin content (p = 0.02, HG-treated MCs vs LG-treated MCs; p = 0.01, TGFβ-treated MCs (+) vs LG-treated MCs, n = 4). (C) Senescence
was evaluated on MCs cultured for 48h as indicated and expressed as the percentage of SA-β-gal-positive cells. Endothelial cells treated
with ox-LDL were used as a positive control (p = 0.01, LG- and HG-treated MCs vs positive control (+), n = 5). (D) Cell extracts fromMCs
treated as above were analysed for collagen type IV content, normalized to β-actin (p = 0.01, HG-treated MCs vs LG-treated MCs;
p = 0.02, TGFβ-treated MCs (+) vs LG-treated MCs, n = 6). (E) Cell supernatants recovered fromMCs treated as above were analysed by
western blot for collagen type IV content (p = 0.01, HG and TGFβ (+) vs LG treated MCs, n = 5). (F) TGFβ content was analysed by
western blot on MCs treated as above. Fibroblasts treated with HG were used as a positive control. Data were normalized to β-actin
content (p = 0.03, HG vs LG treated MCs; p = 0.02, HG-treated fibroblasts vs LG-treated MCs, n = 5). (G)miR‐21 expression was
evaluated by qRT‐PCR on MCs that had been treated as above. Data normalized to RNU6B are representative of six experiments
performed in triplicate (p = 0.02, HG vs LG treated MCs; p = 0,001 TGFβ (+) vs LG-treated MCs). (H) Cell extracts from treated MCs were
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analysed for PTEN and mTOR content and normalized to β-actin content (p = 0.03, HG vs LG and p = 0.01 TGFβ vs LG treated MCs for
PTEN; p = 0.04, HG and TGFβ vs LG treated MCs for mTOR, n = 4).
doi:10.1371/journal.pone.0162417.g001
Fig 2. EVs recovered fromMSCs and HLSCs interfere with collagen production andmiR-21 expression in MCs. (A) Cell proliferation was
assayed in MCs that had been cultured for 48h in either LG or HG conditions, then starved and either treated with the indicated EVs for 18h or left
untreated. Data are reported as number of cells per field (20X magnification) and expressed as mean±SEM (n = 5) (p = 0.006, HG vs LG treated
MCs). (B) Cell extracts fromMCs treated as in A were analysed for collagen type IV content and normalized to β-actin content (n = 5) (p = 0.04, HG
vs LG treated MCs; p = 0.03, HG-treated MCs+MSC-EVs vs HG-treated MCs; p = 0.02, HG-treated MCs + HLSC-EVs vs HG-treated MCs). (C)
miR‐21 expression was evaluated by qRT‐PCR on 48h LG- or HG-cultured MCs, either untreated or treated with MSC-EVs or HLSC-EVs for 18h.
Data normalized to RNU6B are representative of six experiments performed in triplicate (n = 6) (p = 0.01, HG vs LG treated MCs; p = 0.04, HG-
treated MCs+MSC-EVs vs HG-treated MCs; p = 0.04, HG-treated MCs+HLSC-EVs vs HG-treated MCs). (D) Cell extracts fromMCs treated as
above were analysed for PTEN and mTOR content and normalized to β-actin (p = 0.005, HG vs LG treated MCs; p<0.001, HG-treated MCs
+MSC-EVs vs HG-treated MCs; p = 0.001, HG-treated MCs+HLSC-EVs vs HG-treated MCs for PTEN; p<0.001, HG vs LG treated MCs; p<0.001,
HG-treated MCs+MSC-EVs vs HG-treated MCs; p = 0.004, HG-treated MCs+HLSC-EVs vs HG-treated MCs for mTOR, n = 6). (E)Cell extracts
fromMCs treated as indicated were analysed for TGFβ content, normalized to β-actin (n = 5) (p = 0.03, HG vs LG treated MCs; p = 0.01, HG-
treated MCs+MSC-EVs vs HG-treated MCs; p = 0.008, HG-treated MCs+HLSC-EVs vs HG-treated MCs).
doi:10.1371/journal.pone.0162417.g002
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MSC- and HLSC-derived EVs regulate STAT5A expression in MCs
subjected to HG
We have previously shown that delayed (48 hours) HG treatment leads to STAT5 activation in
MCs [33]. It has been shown that miR-21 expression falls under the control of STAT5 in
response to prolactin [17]. The observation that EVs derived fromMSCs and HLSCs affect miR-
21 expression has led us to investigate whether STAT5 may be involved in its regulation. To this
purpose, MCs treated with HG were analysed for STAT5A activation, either in the presence or
absence of EVs. As shown in Fig 3A, STAT5A underwent activation in response to HG treat-
ment, but this effect was inhibited by EV treatment (Fig 3B). The observation that reduced
Fig 3. MSC- and HLSC-derived EVs drive STAT5A expression in MCs. (A-C)Cell extracts from 48h LG- or HG-cultured MCs treated with
either MSC-EVs or HLSC-EVs for 18h were analysed for pSTAT5A and STAT5A content, normalized to β-actin (n = 4) (p = 0.03, HG vs LG
treated MCs; p = 0.02, HG-treated MCs+MSC-EVs vs HG-treated MCs; p = 0.01, HG-treated MCs+HLSC-EVs vs HG-treated MCs for
pSTAT5A in B. p = 0.04, HG vs LG treated MCs; p = 0.01, HG-treated MCs+MSC-EVs vs HG-treated MCs; p = 0.03, HG-treated MCs
+HLSC-EVs vs HG-treated MCs for STAT5A inC). (D) Cell extracts fromMCs cultured for 48h with HG and either transfected with
ΔNSTAT5 construct, with the empty vector (48h) or not at all were subjected to SDS-PAGE to evaluate pSTAT5A content, normalized to
STAT5A content (n = 4) (p<0.001, ΔNSTAT5 vs none and empty vector). (E)miR‐21 expression was evaluated by qRT‐PCR on MCs treated
as in D. Data normalized to RNU6B are representative of six experiments performed in triplicate (n = 6) (p = 0.01, ΔNSTAT5 vs none and
empty vector). (F) Cell extracts from HG-cultured MCs, either transfected with ΔNSTAT5 construct, with the empty vector for 48h or not at all,
were analysed for TGFβ and collagen type IV content, normalized to β-actin (n = 5) (p<0.001, ΔNSTAT5 vs none and empty vector for TGFβ
and collagen type IV).
doi:10.1371/journal.pone.0162417.g003
Stem Cell EVs Drive Protection in a Hyperglycaemic Setting
PLOS ONE | DOI:10.1371/journal.pone.0162417 September 9, 2016 8 / 18
STAT5A expression was detected in these experimental conditions (Fig 3C) enforces the possibil-
ity that EV cargo regulates its expression. In order to investigate this possibility further, a
ΔNSTAT5 construct was transfected into MCs (Fig 3D) and miR-21 expression was analysed. As
reported in Fig 3E, the inhibition of STAT5A activation leads to miR-21 down-regulation in HG-
cultured MCs. Moreover, collagen production was found to be almost completely suppressed
when analysed in these experimental conditions (Fig 3F). Interestingly, we also found that the
inhibition of the STAT5 signalling pathway prevents HG-mediated TGFβ expression (Fig 3F).
EVmiR cargo regulates STAT5A expression
MSC and HLSC EV miRnomics have been previously reported [27]. We evaluated whether
EV-borne-miRs, and in particular miR-223 and miR-222, are relevant to regulating the signal-
ling pathway that is activated by HG. It has been reported that both miR-223 and miR-222
post-transcriptionally regulate STAT5 [18–20], which led us to evaluate their expression in
HG-cultured, EV treated MCs. Whereas miR-222 is down regulated upon HG treatment and
increased upon EV treatment (Fig 4A), miR-223 increased upon both HG and EV treatment
(Fig 4B). Gain-of function experiments were performed in MCs transfected with pre-miR-222
or pre-miR-223 and cultured in LG or HG conditions (S1A and S1B Fig), in order to evaluate
which miR was able to regulate STAT5 expression. Interestingly, only miR-222 over-expression
reduced STAT5A expression and activation, the consequent miR-21 level, TGFβ expression
and collagen production in HG-treated MCs (Fig 4C–4H). The luciferase assay further sup-
ports the role of miR-222 in driving STAT5 post-transcriptional regulation (Fig 4F). More
importantly, such events did not occur in LG-cultured MCs. The transfer of miR-222 into MCs
by EVs was demonstrated by experiments performed in the presence of α-amanitin, using EVs
that had either been pre-treated with RNAse or not at all (S1C Fig).
EV-mediated miR-21 down-regulation can promote miR-100 post-
transcriptional activity which contributes to the inhibition of collagen
production
The dual findings that miR-100 is also carried by MSC- and HSC-derived EVs [27], and that
miR-100 post-transcriptionally regulates mTOR [37], led us to investigate whether it can also
contribute to EV-mediated effects. First, miR-100 expression was evaluated in MCs subjected to
EV treatment. As shown in Fig 5A, while miR-100 MC content increased upon HG treatment,
no changes in its content were detected after EV treatment. However, as the balance of intracel-
lular miRs directs specific biological responses, we hypothesized that the decreased miR-21
intracellular content associated with EV treatment could favour miR-100 post-transcriptional
activity. To validate this hypothesis, gain-of function experiments using pre-miR-100 were per-
formed in HG-treated MCs (Fig 5B). Indeed, data reported in Fig 5C and 5D demonstrate that
miR-100 can, when its expression is favoured with respect to miR-21, drive signals, mediated by
mTOR down-regulation, which result in the inhibition of MC TGFβ expression and collagen
production. The effect of miR-100 over-expression did not further increase after EVs treatment
(data not shown). Again, miR-100 over-expression did not impact on LG-cultured MCs (Fig 5C
and 5D). Collectively, these data indicate that the fine tuning of miR content in recipient cells
during EV treatment, might also contribute to the healing properties delivered.
EV treatment boosts mitocondrial CoxIV expression in HG treated cells
The disturbance of mitochondrial homeostasis is a key event in HG-induced cellular damage
[38]. The role of miR-21 in mitochondrial disorder has previously been reported [39]. We
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Fig 4. miR-222 EV cargo drives STAT5A expression in HG-cultured MCs. (A-B)miR‐222 (A) and miR-223 (B) expression was evaluated by qRT‐
PCR on 48h LG- or HG-cultured MCs, that had either been treated with MSC-EVs or HLSC-EVs for 18h or otherwise left untreated. Data normalized to
RNU6B are representative of six experiments performed in triplicate (n = 6) (p = 0.04, HG vs LG; p = 0.001, HG-treated MCs+MSC-EVs vs HG-treated
MCs; p = 0.01, HG-treated MCs+HLSC-EVs vs HG-treated MCs inA: p = 0.02, HG vs LG; p = 0.01, HG-treated MCs+MSC-EVs vs HG-treated MCs;
p = 0.007, LG-treated MCs+HLSC-EVs vs LG-treated MCs inB). (C) Cell extracts fromMCs, transfected with either pre-miR neg control or pre-miR-222
and cultured in either a LG or HGmedium were subjected to SDS-PAGE and analysed for pSTAT5A, STAT5A TGFβ and collagen type IV content,
normalized to β-actin content. (D) Densitometric analysis was performed on western blots of MCs treated as above (n = 5) (LG pre-miR neg control vs
HG pre-miR neg c, p = 0.01 for pSTAT5A, STAT5A, TGFβ and collagen type IV content; HG pre-miR neg c vs HG pre-miR-222, p<0.001 for pSTAT5A,
STAT5A, TGFβ and collagen type IV). (E)miR‐21 expression was evaluated by qRT‐PCR on MCs, transfected with pre-miR neg c or pre-miR-222,
cultured in either a LG or HGmedium. Data were normalized to RNU6B (five experiments performed in triplicate, n = 5) (p = 0.002, LG pre—miR neg c
and LG pre-miR-222 vs HG pre-miR neg c; p = 0.04, pre-miR-222 vs pre miR neg in HG). (F)MCs were either transfected with pGL3 empty vector or
Stem Cell EVs Drive Protection in a Hyperglycaemic Setting
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therefore decided to evaluate whether EVs were able to prevent the mitochondrial damage that
is associated with HG-treatment. To this purpose, the expression of the CoxIV protein, one of
the nuclear encoded mitochondrial electron transport chain (ETC) components, was evaluated
in LG- or HG-cultured MCs that had either been treated with EVs or not at all. It was found
pGL3‐30‐UTR-full length-STAT5A luciferase constructs, treated as indicated. Relative luciferase activity is reported as mean±SEM (n = 4) (p = 0.004, LG
pre-miR neg c vs HG pre-miR neg c for pGL3-3’UTR-STAT5A; p = 0.01, HG pre-miR-222 vs HG pre miR neg c). (G) Cell extracts from LG- or HG-
cultured MCs, transfected with pre-miR neg control or pre-miR-223, were subjected to SDS-PAGE and analysed for pSTAT5A, STAT5A, TGFβ and
collagen type IV content, normalized to β-actin content. (H) Densitometric analysis was performed on western blots of MCs treated as above (n = 5) (LG
pre-miR neg c vs HG pre-miR neg c, p = 0.01 for pSTAT5A, STAT5A and TGFβ content; p = 0.05, for collagen type IV content).
doi:10.1371/journal.pone.0162417.g004
Fig 5. Over-expression of miR-100 in HG-treated MCs impairs mTOR and TGFβ expression and collagen
production. (A)miR-100 expression was evaluated by qRT-PCR on 48h LG- and HG-cultured MCs, either alone or in
combination with MSC-EVs or HLSC-EVs for 18h. Data normalized to RNU6B are representative of four different
experiments performed in triplicate (n = 4). (p = 0.04, LG vs HG treated MCs). (B)Gain-of-function experiments were
performed on MCs cultured in LG or HGmedium for 48h, using pre-miR-100 oligonucleotides. Pre-miR negative control
(neg c) oligonucleotides were used as control. miR-100 expression was evaluated by qRT-PCR and normalized to
RNU6B (five experiment performed in triplicate, n = 5) (p = 0.003, pre-miR-100 vs pre miR neg in LG; p = 0.002 pre-miR-
100 vs pre miR neg in HG. (C) Cell extracts fromMCs cultured in either a LG or HGmedium and transfected with either
pre-miR neg c or pre-miR-100 were subjected to SDS-PAGE and analysed for mTOR, TGFβ and collagen type IV
content, normalized to β-actin. (D) Densitometric analysis was performed on western blots of MCs treated as above
(n = 6) (LG pre-miR neg c vs HG pre-miR neg c, p = 0.02 for mTOR, p = 0.03 for TGFβ and p = 0.01 for collagen type IV
content; HG pre-miR neg c vs HG pre-miR-100, p<0.001 for mTOR, TGFβ and collagen type IV content).
doi:10.1371/journal.pone.0162417.g005
Stem Cell EVs Drive Protection in a Hyperglycaemic Setting
PLOS ONE | DOI:10.1371/journal.pone.0162417 September 9, 2016 11 / 18
that HG, unlike LG, reduced CoxIV expression. It is worth noting that EV administration can
rescue CoxIV expression in HG-cultured MCs (Fig 6A). In order to investigate the role of miR-
21 in regulating CoxIV expression, LG-cultured MCs were transfected with pre-miR-21 and
analysed for CoxIV content. Interestingly, CoxIV expression was not affected by miR-21 over-
expression (S1D Fig) in this experimental condition (Fig 6B). This suggests that miR-21 over-
expression alone could be still balanced by a compensatory cell response [40]. As a matter of
fact, a low CoxIV level was detected in HG-treated MCs that had been transfected with anti-
miR-21 oligonecleotides (Fig 6B and S1E Fig).
Discussion
The present study shows that EVs released from MSCs and HLSCs protect MCs from HG-
induced collagen production. In particular, we found that EVs that transfer miR-222 regulate
STAT5A expression that in turn controls miR-21 and TGFβ expression as well as matrix pro-
tein synthesis. Moreover, we provide evidence that EVs may also indirectly contribute to the
inhibition of collagen production by driving changes in the balance between miR-21 and miR-
100 in the recipient cell. Finally, we demonstrate that EVs can also save MCs from harmful
mitochondrial signals. These results indicate that both MSC-and HLSC-derived EVs can trans-
fer/activate the machinery needed to preserve MCs from HG-mediated damage.
The renal structural alterations in DN are characterized by an early high proliferation rate
of both glomerular and tubular cells and the late accumulation of extracellular matrix proteins,
such as collagen IV and fibronectin, which lead to progressive mesangial expansion [5,41].
Hyperglycaemia plays a crucial role in these processes and a number of mechanisms have
been proposed [5,10,41]. MC proliferation is an early indicator of DN progression [5,10] and,
Fig 6. EV treatment boosts mitochondrial CoxIV expression in HG-treated cells. (A) LG- or HG-cultured
MCs, that had either been treated with MSC-EVs, HLSC-EVs or not at all, were lysed in a RIPA buffer and
analysed for CoxIV content, normalized to β-actin (n = 4) (p = 0.002, LG vs HG treated MCs; p = 0.04, HG-
treated MCs+MSC-EVs vs HG-treated MCs; p = 0.02, HG-treated MCs+HLSC-EVs vs HG-treated MCs). (B)
LG-cultured MCs that had been transfected with either pre-miR neg control or pre-miR-21 and HG-cultured
MCs transfected with either anti-miR neg control or anti-miR-21 were lysed in a RIPA buffer and subjected to
SDS-PAGE to evaluate CoxIV content, normalized to β-actin (n = 5).
doi:10.1371/journal.pone.0162417.g006
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as shown herein, HG induces MC proliferation. TGFβ has been recognized as the most relevant
regulatory cytokine in the onset of MC collagen accumulation [42–44]. Indeed, 48 hour HG
treatment led to TGFβ expression and collagen production. Likewise, miR-21, one of the most
relevant miRs in the control of fibrogenic processes, was up-regulated upon HG treatment.
miR-21 is over-expressed in a different model of fibrosis and diverse pathways drive its expres-
sion [6,9,11]. miR genes are regulated by transcriptional factors [15], just like other genes. The
miPPR21 gene is targeted by STAT3 [45], and STAT5 [17], which may initiate opposing bio-
logical actions; STAT3 inhibits, whereas STAT5 induces,miPPR21 gene transcription [17,45].
In this regard, STAT5 binding to themiPPR-21 gene has been shown to regulate miR-21
expression in Jurkat cells [16], and in mammary cells in response to prolactin [17]. In an exper-
iment that uses data fromWang and collaborators [46], and which is consistent with our previ-
ous report [33], we have found that HG treatment induces delayed STAT5 activation, which
occurs after 48 hours of treatment. This observation led us to investigate the impact of STAT5
on miR-21 expression. Indeed, MCs that are unable to activate STAT5A also failed to increase
miR-21 content in response to HG. Moreover, we demonstrate that this effect translates into
the inhibition of TGFβ expression and collagen production. These data are in line with the
results published by Wang et al. [46], which show that a JAK2 blockade was only effective in
inhibiting STAT5 activation 48 hours after HG treatment. Moreover, such delayed STAT5 acti-
vation kinetics could also explain our previous data [33]. Collectively, these results identify
STAT5A as the transcriptional regulator of miR-21 which, in turn, impacts on TGFβ expres-
sion and collagen production in MCs subjected to HG. Moreover, since HG treatment recapit-
ulates DM-induced MC damage, MCs might be a good cell model with which to assess the
efficacy of novel therapeutic options. This would be of particular interest as so far as DN is
becoming the leading cause of ESRD despite strict metabolic control and the application of var-
ious beneficial approaches and novel therapeutic options [4].
Regenerative medicine and, in particular, cell-based therapy have recently attracted special
attention and various cell types have been proposed, including mesenchymal stem cells
(MSCs) of different origin [21,47]. Their particular properties make MSC-derived extracellu-
lar vesicles (EVs) a promising new therapeutic option. Adult human stem cells, including
MSCs and HLSCs, secrete EVs which contain specific subsets of functional miRs [27], with
healing properties [24]. We herein demonstrate that EVs released from both MSCs and
HLSCs can interfere with the signalling pathways activated in MCs by the hyperglycaemic
microenvironment. In particular, we demonstrate that the transfer of EV cargo into MCs
leads to reduced STAT5 expression/activation, the down-regulation of miR-21 and TGFβ
expression which ultimately results in a reduction of MC collagen production. Furthermore,
EV treatment was found to be associated with mTOR down-regulation. The direct EV-medi-
ated delivery of miRs was discovered to affect the translation of target mRNA, which suggests
that they may control cell biology [22,23,27,30]. An analysis of EV miR content in both cellu-
lar sources identified miR-222 and miR-223 [27]. It has been shown that the STAT5 protein
level is modulated by both miRs in different cellular contexts and that STAT5 is a direct miR-
222 and miR-223 target [18–20]. This highlighted a role that miR-222, miR-223 or both may
play in the post-transcriptional regulation of STAT5A upon EV treatment. Indeed, although
both miRs increased in MCs that had been subjected to EV challenge, only miR-222 over-
expression seems to be relevant in driving EV biological response in MCs. As a matter of fact,
over-expressing miR-222, but not miR-223 led to a STAT5A level that was almost undetect-
able, miR-21 that was down-regulated as well as TGFβ expression and collagen production
that were barely discernible. Moreover, experiments into transcription blockades by alpha-
amanitin suggested that miR-222 expression in MCs relied on the transfer of this specific miR
from EVs into recipient cells. Of particular interest is the fact that miR-222 over-expression
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did not have an effect on LG-cultured MCs. These results are consistent with the notion that
miR(s) transferred into a recipient cell may drive discrete biological programs [48], depending
on the target cell and specific biological context. EVs have also been shown to display a thera-
peutic effect via the transfer of various miRs with protective activity [22,23,27,30]. Other
potential therapeutic miRs were identified by investigating MSC and HLSC EV content,
including miR-100 [27], which has been shown to target mTOR [37]. Although miR-100 con-
tent increases in HG-treated MC cells, possibly as a protective mechanism, its expression did
not change upon EV treatment. However, as the balance of intracellular miR content that
occurs after EV treatment is able to change the biological response of the cell, we attempted to
mimic such an event by performing gain-of-function experiments using pre-miR-100. We
herein provide evidence that the increase in miR-100 content in HG-treated cells is associated
with the reduced expression of mTOR, TGFβ and collagen production. Although the biologi-
cal effects exerted by EV administration are under extensive investigations the mechanisms
behind miRs and proteins crosstalk inside the target cell are not completely understood. It is
well established that EVs may modulate target cell functions by delivering a variety of miRs
which alone or in combination could change recipient cell epigenome [24]. This is particularly
true for miR-222 which post-transcripionally regulates STAT5 expression and indirectly
miPPR21 gene expression and miR-21 cellular content, via STAT5 transcriptional activity.
This, in turn, by changing the balance between miR-21 and miR-100, may result in miR-100
post-transcriptional regulation of mTOR. We did not provide data on a direct correlation
between miR-21 and miR-100. However, the results of the present study suggest that EVs, by
transferring their cargo, might exert a fine tuning effect on endogenous miRs which may even-
tually translate in additional healing properties.
Different mechanisms can account for the failure of EVs to influence LG-MC functional
behaviour. Differences in gene expression are expected in MCs subjected to LG and HG. There-
fore, it is tempting to hypothesize that EV treatment may virtually inhibit HG-mediated gene
expression via mechanisms including RNA interference, giving EVs a precise therapeutic
potential. This may confer to EVs additional therapeutic benefits to EVs by overcoming the
major safety concerns.
Mitochondrial dysfunction plays a crucial role in HG-mediated damage [38]. We herein
report that HG treatment is associated with the down-regulation of a nuclear encoded mito-
chondrial ETC component, CoxIV. It has been suggested that the expression of ETC compo-
nent(s) could compensate harmful cues [38]. It is worth noting that EV administration boosted
CoxIV expression, indicating that the fine-tuning of CoxIV can be driven by EV-mediated
miR-21 down-regulation. Indeed, miR-21 is known to be involved in mitochondrial functional
activity [39]. However, our results on LG-cultured MCs that over-express miR-21 and HG-cul-
tured cells depleted of miR-21 indicate that changes in the intracellular miR-21 content cannot
account for the deranged mitochondrial function in the hyperglycaemic setting on their own.
Nevertheless, the results presented herein suggest that EVs can also protect MCs from harmful
mitochondrial signals by transferring their cargo in a hyperglycaemic setting.
EVs are recognized as an integral component of the cell-to-cell communication network
involved in tissue regeneration [49] and may actively transfer various molecules to target cells.
The consequent modulation of cell phenotype is mainly due to transcriptional and stable epige-
netic changes [50]. Indeed, we herein demonstrate that EVs released fromMSCs and HLSCs
display therapeutic potential in protecting MCs from HG-mediated collagen production. This
occurs via the horizontal transfer of functional miR-222, and direct interference with damaging
cues (Fig 7). Moreover, the results of the present study indicate that the release of EV cargo
into the recipient cell may provide additional therapeutic advantages, including interference
with mitochondrial dysfunction, by altering the balance of endogenous miR(s).
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Supporting Information
S1 Fig. Gain- and loss-of-function experiments. (A-B) Gain-of-function experiments were
performed on MCs that had either been cultured in LG or HG medium for 48h, using pre-
miR-222 (A) or premiR-223 (B) oligonucleotides. Pre-miR negative control (neg c) oligonucle-
otides were used as a control. miR-222 and miR-223 expression was evaluated by qRT-PCR
and normalized to RNU6B (five experiment performed in triplicate, n = 5) (p = 0.04, pre-miR-
222 vs pre miR neg c in LG; p = 0.001, pre-miR-222 vs pre miR neg in HG in A; p = 0.012, pre-
miR-223 vs pre miR neg c in LG; p = 0.004, pre-miR-223 vs pre miR neg in HG in B). (C) MCs
incubated in the presence of 50 μg/ml of α-amanitin to inhibit MC transcription were either
stimulated with MSC-EVs, HLSC-EVs or not at, all as well as being pre-treated with RNAse or
left untreated. EV-miR-222 transfer was evaluated by q-RT-PCR. The difference in Ct values
(ΔCt) between α-amanitin-treated MCs alone or those with the indicated EVs is reported
(p<0.001) (mean±SEM). (D-E) miR-21 expression was evaluated using qRT-PCR and
Fig 7. Schematic representation of the mechanisms through which MSC/HLSCmicroRNA-carrying vesicles protect MCs
from collagen production in hyperglycaemic setting.Hyperglycaemic conditions lead to matrix production via STAT5A and miR-
21 up-regulation. This translates into PTEN/mTOR and TGFβ expression and collagen type IV production. MC treated with MSC- and
HLSC-derived EVs are protected from fibrogenic signals via the release of EV cargo; miR-222 post-transcriptionally regulates
STAT5A which in turn controls miR-21 expression. Changes in the balance between miR-21 and miR-100 may also contribute to EV
action. Finally, MSC- and HLSC-EV treatment also saves MCs from harmful mitochondrial signals by up-regulating CoxIV expression.
doi:10.1371/journal.pone.0162417.g007
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normalized to RNU6B (five experiments performed in triplicate, n = 5) on LG-cultured MCs
transfected with either pre-miR neg c or pre-miR-21, and on HGcultured MCs transfected
with either anti-miR negative control or anti-miR-21 (p = 0.03, pre-miR-21 vs pre miR neg c in
LG in D; p = 0.02, anti-miR-21 vs anti-miR neg in HG in E).
(PDF)
S1 Table. Reagents and antibodies.
(DOCX)
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